Merck & Co (MRK) return on equity (ROE)

Return on equity · fiscal 2025
34.7%

Merck & Co (MRK) earned a return on equity of 34.7% in fiscal 2025 (the year ended December 31, 2025). That is 2.3 percentage points lower than the 37.0% of fiscal 2024. Figures as of 17 Nov 2026, 22:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
34.7%
Change on fiscal 2024
−2.3 pts
Highest on record
41.6%fiscal 2008
Lowest on record
1.0%fiscal 2023
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Merck & Co return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 41.6% in fiscal 2008 and the lowest 1.0% in fiscal 2023. The fiscal 2025 figure is higher than in 83% of the 18 earlier fiscal years on record, whose median is 18.9%.

History · 19 fiscal years

Return on equity by fiscal year

Merck & Co return on equity (ROE), year by year

Merck & Co (MRK) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202534.7% 2.3 pts down
202437.0% 36.0 pts up
20231.0% 30.6 pts down
202231.6% 2.6 pts down
202134.2% 6.3 pts up
202027.9% 10.1 pts down
201938.0% 14.7 pts up
201823.3% 16.3 pts up
20177.0% 2.8 pts down
20169.8% 0.2 pts down
20159.9% 14.6 pts down
201424.5% 15.7 pts up
20138.8% 2.8 pts down
201211.6% 0.1 pts up
201111.5% 9.9 pts up
20101.6% 20.3 pts down
200921.8% 19.8 pts down
200841.6% 25.7 pts up
200715.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Merck & Co and comparable companies
CompanyReturn on equityFiscal year
Johnson & Johnson JNJ32.9%2025
AbbVie ABBV128.7%2024
Merck & Co MRK34.7%2025
UnitedHealth Group UNH12.8%2025
Novartis NVS30.3%2025
AstraZeneca AZN21.0%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on MRK

Merck & Co, figure by figure

Merck & Co (MRK) overview: price, valuation and scorecardAll health care companies by market value

Merck & Co return on equity (ROE): questions and answers

What is Merck & Co's return on equity?

Merck & Co (MRK) earned a return on equity of 34.7% in fiscal 2025 (the year ended December 31, 2025). That is 2.3 percentage points lower than the 37.0% of fiscal 2024.

Is Merck & Co's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 83% of the 18 earlier fiscal years on record, whose median is 18.9%.

What are the highest and lowest return on equity figures on record for Merck & Co?

Across the 19 fiscal years on record (2007–2025), the highest was 41.6% in fiscal 2008 and the lowest 1.0% in fiscal 2023.

How is Merck & Co's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Merck & Co (MRK) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/MRK/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.